Nanotechnology Now - Press Release: Nanogen to Host Second Quarter Conference Call and Webcast on August 8, 2007

Home > Press > Nanogen to Host Second Quarter Conference Call and Webcast on August 8, 2007

Abstract:
Nanogen, Inc. (Nasdaq:NGEN), developer of advanced diagnostic products, will host a conference call on Wednesday, August 8, 2007 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2007 second quarter financial results. The financial results press release will be issued at close of market on August 8. Interested investors and others may participate in the conference call by dialing 888.679.8034 for US/Canada participants and 617.213.4847 for international participants. The conference ID will be 55639855.

Nanogen to Host Second Quarter Conference Call and Webcast on August 8, 2007

SAN DIEGO, CA | Posted on August 6th, 2007

Audio of management's presentation will be available via live webcast on the investor relations section of Nanogen's corporate website at www.nanogen.com, and will be archived for one year. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on August 8, and can be accessed via telephone at 888-286-8010 for US/Canada participants and 617-801-6888 for international participants. The conference ID, 89667194, will be required to listen to the playback.

####

About Nanogen, Inc.
Nanogen’s advanced technologies provide researchers, clinicians and physicians worldwide with improved methods and tools to predict, diagnose, and ultimately help treat disease. The company's products include real-time PCR reagents, the NanoChip® electronic microarray platform and a line of rapid, point-of-care diagnostic tests. Nanogen’s ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefense applications. For additional information please visit Nanogen’s website at http://www.nanogen.com .

Nanogen Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.

For more information, please click here

Contacts:
Nanogen, Inc.
Robert Saltmarsh
Chief Financial Officer
858-410-4600
or
Suzanne Clancy
Corporate Communications
858-410-4688

or
Porter Novelli Life Sciences
Kim Richards
Media & Investor Relations
619-849-5377